Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) - Stock analysts at Leerink Partnrs raised their Q3 2025 earnings per share estimates for Privia Health Group in a report released on Tuesday, September 23rd. Leerink Partnrs analyst W. Mayo now forecasts that the company will earn $0.09 per share for the quarter, up from their previous estimate of $0.08. The consensus estimate for Privia Health Group's current full-year earnings is $0.14 per share.
Several other equities analysts have also commented on the company. Stephens reaffirmed an "overweight" rating and set a $32.00 target price on shares of Privia Health Group in a report on Thursday, September 4th. Barclays upped their target price on Privia Health Group from $23.00 to $24.00 and gave the company an "equal weight" rating in a report on Tuesday, May 27th. Piper Sandler lowered their target price on Privia Health Group from $36.00 to $35.00 and set an "overweight" rating for the company in a report on Monday, August 11th. JMP Securities boosted their price objective on Privia Health Group from $29.00 to $30.00 and gave the stock a "market outperform" rating in a research report on Friday, August 29th. Finally, JPMorgan Chase & Co. boosted their price objective on Privia Health Group from $29.00 to $32.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $28.58.
Check Out Our Latest Stock Analysis on PRVA
Privia Health Group Trading Up 2.5%
NASDAQ:PRVA opened at $23.48 on Wednesday. The firm has a market capitalization of $2.88 billion, a PE ratio of 213.47, a price-to-earnings-growth ratio of 3.32 and a beta of 0.82. The stock has a 50 day moving average of $21.33 and a 200-day moving average of $22.40. Privia Health Group has a 52 week low of $16.47 and a 52 week high of $26.09.
Privia Health Group (NASDAQ:PRVA - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.05 by ($0.03). The company had revenue of $521.15 million for the quarter, compared to the consensus estimate of $466.97 million. Privia Health Group had a net margin of 0.78% and a return on equity of 2.13%. The firm's revenue for the quarter was up 23.4% compared to the same quarter last year. During the same period last year, the company posted $0.19 earnings per share. Privia Health Group has set its FY 2025 guidance at EPS.
Hedge Funds Weigh In On Privia Health Group
A number of hedge funds have recently modified their holdings of PRVA. Van Berkom & Associates Inc. acquired a new position in shares of Privia Health Group in the 1st quarter worth $45,207,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Privia Health Group by 180.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,633,040 shares of the company's stock valued at $59,112,000 after purchasing an additional 1,693,870 shares during the period. Nuveen LLC acquired a new stake in Privia Health Group during the 1st quarter valued at $26,899,000. Royce & Associates LP acquired a new stake in Privia Health Group during the 1st quarter valued at $6,818,000. Finally, Qube Research & Technologies Ltd raised its stake in Privia Health Group by 93.3% during the 2nd quarter. Qube Research & Technologies Ltd now owns 609,278 shares of the company's stock valued at $14,013,000 after purchasing an additional 294,101 shares during the period. 94.48% of the stock is currently owned by institutional investors and hedge funds.
About Privia Health Group
(
Get Free Report)
Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Privia Health Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Privia Health Group wasn't on the list.
While Privia Health Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
